Login

NON-SUBSCRIBER OPTIONS
FREE TRIAL   |   NEWSSTAND

Home

SCOTUS Coverage

10 SCOTUS Cases Mentioned At King Hearing That Could Shape Justices' Ruling

In the course of oral arguments in King v. Burwell at the U.S. Supreme Court on Wednesday (March 4), justices and lawyers alike suggested past litigation that could serve as precedents in shaping how the high court ultimately rules. Following is Inside Health Policy's rundown of 10 cases that were mentioned, what their original rulings said and how they played into this week's hearing on whether the health law's insurance subsidies are available in federally run exchanges -- from the original ruling that upheld the Affordable Care Act's “individual mandate” to a recent case around a woman who tried to poison her husband's lover.

Latest News

FDA could decide on the first U.S. biosimilar -- Sandoz's biosimilar of Amgen's Neupogen -- as soon as Sunday (March 8), but the expected approval doesn't mean the product will be available anytime soon or even be less expensive than the brand product, court documents indicate.

FDA Commissioner Margaret Hamburg said the agency will put out biosimilar guidances and decisions that may touch on important topics -- such as naming, labeling and interchangeability -- very soon, following “lots of meetings with prospective companies” and as the agency reviews five biosimilar applications that have been taken up by the agency.

CMS' Patrick Conway hinted at the direction CMS is taking on the next generation of accountable care organizations at a recent meeting on Capitol Hill. Conway spent more time talking about changes CMS is considering for advanced ACOs that accept the risk of financial penalties, but he also told Inside Health Policy that CMS is considering similar changes for so-called one-sided risk ACOs that share in savings without the risk of being penalized for missing cost and quality-of-care targets.

House Republican appropriators signaled Wednesday (March 4) that FDA is highly unlikely to get its requested $425 million combined funding bump of direct budget authority and new user fees for fiscal 2016.

FDA Commissioner Margaret Hamburg told House lawmakers Wednesday (March 4) that a guidance on evaluation and labeling of abuse-deterrent opioid drugs will be finished by appropriators' June 30 deadline -- or possibly even sooner.

A Supreme Court ruling late last month against the North Carolina Board of Dental Examiners could expand scope of practice for others in the health industry, including nurse practitioners, whose activities have limited by such boards, stakeholders say.

The nation's largest physician lobbying group and 99 state and specialty societies asked CMS Wednesday (March 4) to create a plan for handling a potential flood of rejected claims when the new billing-code system takes effect in October.

Congressional Medicare advisers on Thursday (March 5) will discuss whether the 45 percent of Medicare acute care hospitals in the 340B drug discount program should be paid lower rates for administering drugs in outpatient departments, according to the meeting agenda.